[Form 4] Annovis Bio, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Annovis Bio (ANVS) Vice President of Finance Andrew Walsh reported a new acquisition of company shares on Form 4. The transaction details include:

• Acquired 500 shares of Common Stock
• Purchase price: $2.90 per share
• Transaction date: June 16, 2025
• Total transaction value: $1,450
• Ownership type: Direct

Following this transaction, Walsh holds 500 shares directly. The purchase represents an initial position for the executive, as no prior holdings were reported. The transaction was reported within the required two-business-day filing window, with the Form 4 being filed on June 28, 2025. No derivative securities were involved in this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walsh Andrew

(Last) (First) (Middle)

C/O ANNOVIS BIO, INC.

101 LINDENWOOD DR, SUITE 225

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Vice President, Finance

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/16/2025		A		500	A	$2.9	500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Andrew Walsh	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares of ANVS stock did Andrew Walsh acquire on June 16, 2025?

According to the Form 4 filing, Andrew Walsh acquired 500 shares of ANVS common stock on June 16, 2025 at a price of $2.90 per share.

What position does Andrew Walsh hold at ANVS (Annovis Bio)?

Andrew Walsh serves as Vice President, Finance at Annovis Bio, Inc. (ANVS) as disclosed in the Form 4 filing.

What was the total value of Andrew Walsh's ANVS stock purchase on June 16, 2025?

The total value of Andrew Walsh's stock purchase was $1,450, calculated from 500 shares acquired at $2.90 per share.

How many shares of ANVS does Andrew Walsh own following this transaction?

Following this transaction, Andrew Walsh directly owns 500 shares of ANVS common stock, held in Direct (D) ownership form.

Did Andrew Walsh acquire any derivative securities of ANVS in this Form 4 filing?

No, the Form 4 filing shows no acquisition or disposition of derivative securities (such as options or warrants) by Andrew Walsh. The transaction only involved common stock.